Paid Clinical Trials Indianapolis

Discover 890 paid clinical trials in Indianapolis, Indiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 890

ImmunotherapyImmunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Recruiting

PHASE1

Sponsor:

Sabine Mueller, MD, PhD

Location:

Indianapolis IN, Saint Louis MO, Birmingham AL, Durham NCshow 9 more

Code:

NCT04323046

Conditions

Glioblastoma

Malignant Glioma

Recurrent Glioblastoma

Recurrent Malignant Glioma

Recurrent Grade III Glioma

Eligibility Criteria

Sex: All

Age: 6 - 25

Healthy Volunteers: Not accepted

Interventions

Nivolumab

Quality-of-Life Assessment

Questionnaire Administration

DAY301To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting

PHASE1

Sponsor:

Day One Biopharmaceuticals, Inc.

Location:

Indianapolis IN, Grand Rapids MI, San Antonio TX

Code:

NCT06752681

Conditions

Advanced or Metastatic Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

DAY301

BT8009Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Recruiting

PHASE1

PHASE2

Sponsor:

BicycleTx Limited

Location:

Lafayette IN, Louisville KY, Nashville TN, Cleveland OHshow 10 more

Code:

NCT04561362

Conditions

Urinary Bladder Neoplasm

Triple Negative Breast Neoplasms

Hormone Receptor Positive, HER2-negative Neoplasms

Hormone Receptor Positive, HER2-low Neoplasms

Breast Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BT8009

Pembrolizumab

Crenolanib vs. MidostaurinStudy of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Recruiting

PHASE3

Sponsor:

Arog Pharmaceuticals, Inc.

Location:

Indianapolis IN, Chicago IL, Detroit MI, Iowa City IAshow 17 more

Code:

NCT03258931

Conditions

Newly Diagnosed FLT3 Mutated AML

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Crenolanib

Midostaurin

Cytarabine

Duanorubicin

Observational StudyStudy of Systemic Amyloidosis Presentation and Prognosis

Recruiting

Sponsor:

National Center for Research Resources (NCRR)

Location:

Indianapolis IN

Code:

NCT00004374

Conditions

Amyloidosis

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Nivolumab & TovorafenibNivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting

PHASE2

Sponsor:

Sabine Mueller, MD, PhD

Location:

Indianapolis IN, Chicago IL, Ann Arbor MI, Saint Louis MOshow 11 more

Code:

NCT05465174

Conditions

Craniopharyngioma, Child

Craniopharyngioma

Recurrent Craniopharyngioma

Eligibility Criteria

Sex: All

Age: 1 - 39

Healthy Volunteers: Not accepted

Interventions

Nivolumab

Tovorafenib

MedtronicMedtronic Terminate AF Study

Recruiting

Sponsor:

Medtronic Cardiac Surgery

Location:

Indianapolis IN, Toledo OH, Grand Rapids MI, Saint Louis MOshow 10 more

Code:

NCT03546374

Conditions

Persistent Atrial Fibrillation

Longstanding Persistent Atrial Fibrillation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Surgical Ablation

Cardioblate and Cryoflex hand held devices

LitifilimabA 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

Recruiting

PHASE2

PHASE3

Sponsor:

Biogen

Location:

Indianapolis IN, Cincinnati OH, Chicago IL, Columbus OHshow 51 more

Code:

NCT05531565

Conditions

Subacute Cutaneous Lupus Erythematosus

Chronic Cutaneous Lupus Erythematosus

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Litifilimab

Placebo

Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Indianapolis IN, Avon IN, Carmel IN, Mooresville INshow 715 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Recruiting

PHASE3

Sponsor:

SWOG Cancer Research Network

Location:

Indianapolis IN, Carmel IN, Kokomo IN, Richmond INshow 530 more

Code:

NCT04071457

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide

Daratumumab/rHuPH20